Advanced Soft Tissue Sarcoma with Mark Agulnik, MD Case 2

During a live event, Richard F. Riedel, MD, discussed key efficacy and safety outcomes from the phase 3 DeFi trial in patients with progressing desmoid tumors.

In this episode of Targeted Talks, Edwin Choy, MD, PhD, discussed the FDA approval of afamitresgene autoleucel for the treatment of patients with advanced synovial sarcoma.

During a live event, Richard F. Riedel, MD, discussed Desmoid Tumor Working Group and NCCN guidelines for treating patients with desmoid tumors.

In season 4, episode 5 of Targeted Talks, Alice P. Chen, MD, discusses important studies that are investigating treatment options for alveolar soft part sarcoma.

The FDA’s breakthrough therapy designation for GSK’227 underscores its potential to address the critical unmet needs of patients with relapsed/refractory osteosarcoma.

Elraglusib is undergoing investigation in an open-label, multicenter, phase 1/2 trial for the treatment of patients with Ewing sarcoma.